PROSCA/BLADDR 2020 | Optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?

Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses efforts being made to optimize the treatment of advanced urothelial cancer including novel combinations of immunotherapy + chemotherapy to improve the outcomes of patients. Dr Siefker-Radtke also outlines trial updates of pembrolizumab as well as enfortumab vedotin, an antibody-drug conjugate, in this patient population. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).